Paper39007347
FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia.
Ali A and 8 others. Cancer Res Commun, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia. Papers, record 39007347. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39007347
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| fms-Like Tyrosine Kinase 3 | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Antibodies, Bispecific | Major topic |
| Nanoparticles | Major topic |
| 12E7 Antigen | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Cell Line, Tumor | |
| Xenograft Model Antitumor Assays | |
| Female |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA014089 | NCI NIH HHS | United States | P30CA014089 | PubMed and NIH | NIH RePORTER |
| R01 CA248381 | NCI NIH HHS | United States | R01CA248381 | PubMed and NIH | NIH RePORTER |
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30651634 | Targeting FLT3 mutations in AML: review of current knowledge and evidence. | Leukemia | 2019 | https://conductscience.org/library/papers/30651634 | PubMed |
| 2 | 35422094 | CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML. | Leukemia | 2022 | https://conductscience.org/library/papers/35422094 | PubMed |
| 3 | 1695726 | Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. | Oncogene | 1990 | https://conductscience.org/library/papers/1695726 | PubMed |
| 4 | 22488197 | Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. | J Surg Oncol | 2012 | https://conductscience.org/library/papers/22488197 | PubMed |
| 5 | 11535508 | The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. | Blood | 2001 | https://conductscience.org/library/papers/11535508 | PubMed |
| 6 | 2479542 | The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. | EMBO J | 1989 | https://conductscience.org/library/papers/2479542 | PubMed |
| 7 | 10709783 | CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway. | Immunol Lett | 2000 | https://conductscience.org/library/papers/10709783 | PubMed |
| 8 | 31371417 | Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia. | Haematologica | 2020 | https://conductscience.org/library/papers/31371417 | PubMed |
| 9 | 22147690 | Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. | J Biol Chem | 2012 | https://conductscience.org/library/papers/22147690 | PubMed |
| 10 | 26578439 | Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines. | J Control Release | 2016 | https://conductscience.org/library/papers/26578439 | PubMed |
| 11 | 14961034 | CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. | Leukemia | 2004 | https://conductscience.org/library/papers/14961034 | PubMed |
| 12 | 35680852 | Resistance to targeted therapies: delving into FLT3 and IDH. | Blood Cancer J | 2022 | https://conductscience.org/library/papers/35680852 | PubMed |
| 13 | 37116523 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37116523 | PubMed |
| 14 | 21109889 | Characterizing the size, shape, and compactness of a polydisperse prolate ellipsoidal particle via quadruple-detector hydrodynamic chromatography. | Analyst | 2011 | https://conductscience.org/library/papers/21109889 | PubMed |
| 15 | 33818756 | De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. | Cancer | 2021 | https://conductscience.org/library/papers/33818756 | PubMed |
| 16 | 32916604 | Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma. | Biomaterials | 2020 | https://conductscience.org/library/papers/32916604 | PubMed |
| 17 | 11090077 | Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. | Blood | 2000 | https://conductscience.org/library/papers/11090077 | PubMed |
| 18 | 31665578 | Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31665578 | PubMed |
| 19 | 8637232 | Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. | Leukemia | 1996 | https://conductscience.org/library/papers/8637232 | PubMed |
| 20 | 12010785 | A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. | Blood | 2002 | https://conductscience.org/library/papers/12010785 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41772642 | Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies. | J Transl Med | 2026 | https://conductscience.org/library/papers/41772642 | PubMed |
| 41654885 | Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems. | J Transl Med | 2026 | https://conductscience.org/library/papers/41654885 | PubMed |
| 40427525 | CD99: A Key Regulator in Immune Response and Tumor Microenvironment. | Biomolecules | 2025 | https://conductscience.org/library/papers/40427525 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39007347
GET https://conductscience.org/api/papers/v1/39007347/references?page=2